Helix BioPharma (HBPC.F) Stock Overview
A clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HBPC.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Helix BioPharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.73 |
| 52 Week High | CA$1.73 |
| 52 Week Low | CA$0.59 |
| Beta | -0.68 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 281.14% |
| 3 Year Change | 116.73% |
| 5 Year Change | 45.82% |
| Change since IPO | -87.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| HBPC.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.8% | -0.4% |
| 1Y | 281.1% | 16.7% | 14.0% |
Return vs Industry: HBPC.F exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: HBPC.F exceeded the US Market which returned 12.9% over the past year.
Price Volatility
| HBPC.F volatility | |
|---|---|
| HBPC.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: HBPC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HBPC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Jacek Antas | www.helixbiopharma.com |
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor.
Helix BioPharma Corp. Fundamentals Summary
| HBPC.F fundamental statistics | |
|---|---|
| Market cap | US$127.97m |
| Earnings (TTM) | -US$3.71m |
| Revenue (TTM) | n/a |
Is HBPC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBPC.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$5.21m |
| Earnings | -CA$5.20m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.068 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.1% |
How did HBPC.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 23:20 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Helix BioPharma Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahu Demir | NOBLE Capital Markets, Inc. |